<DOC>
	<DOC>NCT00737867</DOC>
	<brief_summary>The purpose of this study is to explore if the combination of vinorelbine and gemcitabine is better than vinorelbine and carboplatin in the treatment of advanced non-small cell lung cancer, in terms of survival, quality of life and need for palliative radiotherapy.</brief_summary>
	<brief_title>Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Nonsmall cell lung cancer stage IIIB or IV Not eligible for radical radiotherapy or surgery WHO performance status 02 Pregnancy Other clinical active cancer disease ALAT/ALP more than 3 times upper normal limit, bilirubin &gt;1.5 upper limit Bowel disease that causes malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>carboplatin</keyword>
	<keyword>advanced lung cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>